OR WAIT null SECS
March 05, 2019
The acquisition will establish a clinical pipeline for Biogen of gene-therapy candidates in ophthalmology.
March 02, 2019
As biologics continue to push boundaries, the industry needs to take a holistic approach to formulation to ensure success.
Harmonization of best practices and regulatory requirements will enable developers to find the best stability testing approach.
While allogeneic therapies can use existing regulatory and quality frameworks, autologous treatments will require pharma’s adoption of true just-in-time and right-first-time concepts, says consultant James Blackwell.
February 22, 2019
Valitacell and Solentim, have announced a collaboration aimed at the acceleration of discovery and development of biologic drugs and advanced cell therapies.
February 21, 2019
Mustang intends to combine an oncolytic virus with an interleukin-13 Rα2-(IL13Rα2)-specific chimeric antigen receptor to potentially enhance efficacy in treating glioblastoma multiforme.
Teva will apply Insilico’s technology for predictive biomanufacturing to create more efficient biomanufacturing processes.
February 20, 2019
The agency clarified the process for development programs for regenerative medicine therapies.
February 15, 2019
The drug is approved in the United States specifically for treating acquired thrombotic thrombocytopenic purpura, a rare blood-clotting disorder.
The partners will collaborate on the development and commercialization of a B-cell maturation antigen-targeting immunotherapeutic for treating multiple myeloma.